company background image
MEIP

MEI Pharma NasdaqCM:MEIP Stock Report

Last Price

US$0.54

Market Cap

US$72.4m

7D

8.6%

1Y

-79.5%

Updated

16 Aug, 2022

Data

Company Financials +
MEIP fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MEIP Stock Overview

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.

MEI Pharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MEI Pharma
Historical stock prices
Current Share PriceUS$0.54
52 Week HighUS$3.55
52 Week LowUS$0.41
Beta0.85
1 Month Change-4.76%
3 Month Change16.04%
1 Year Change-79.47%
3 Year Change-67.81%
5 Year Change-78.92%
Change since IPO-99.88%

Recent News & Updates

Shareholder Returns

MEIPUS BiotechsUS Market
7D8.6%1.8%4.5%
1Y-79.5%-22.2%-8.9%

Return vs Industry: MEIP underperformed the US Biotechs industry which returned -19.6% over the past year.

Return vs Market: MEIP underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is MEIP's price volatile compared to industry and market?
MEIP volatility
MEIP Average Weekly Movement11.6%
Biotechs Industry Average Movement12.5%
Market Average Movement7.6%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: MEIP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: MEIP's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200076Dan Goldhttps://www.meipharma.com

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.

MEI Pharma, Inc. Fundamentals Summary

How do MEI Pharma's earnings and revenue compare to its market cap?
MEIP fundamental statistics
Market CapUS$72.43m
Earnings (TTM)-US$46.77m
Revenue (TTM)US$36.74m

2.0x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MEIP income statement (TTM)
RevenueUS$36.74m
Cost of RevenueUS$0
Gross ProfitUS$36.74m
Other ExpensesUS$83.51m
Earnings-US$46.77m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.35
Gross Margin100.00%
Net Profit Margin-127.31%
Debt/Equity Ratio0%

How did MEIP perform over the long term?

See historical performance and comparison